2023-06-03 10:08:56
Published
Video length: 2 min.
Article written by
The American Society of Clinical Oncology (ASCO) Congress is currently taking place in Chicago, USA. It brings together, until June 6, the best cancer specialists. At the heart of the discussions, the hope of vaccines once morest cancer, which are the subject of multiple clinical trials.
Immunotherapy has been a major advance in the fight once morest cancer for more than ten years. It is a targeted action, concentrated on tumor cells. Unlike chemotherapy, it spares healthy cells. Its principle: push the immune systemarea of the patient to fight the tumors himself. The injected antibody will put the immune cells and cancer cells in contact that they will destroy. Immunotherapies are becoming more and more sophisticated today.
Several avenues explored
Since 2011, researchers have been constantly improving a therapy called ADC, which combines antibodies and drugs. “These are antibodies that have been modified on which we have grafted an chemotherapy drug”said Jean-Yves Blay, director of the Léon Bérard Center in Lyon and President of the Federation Unicancer. “The antibody, injected intravenously, will go specifically to the tumor cellsales and get the chemotherapy in there”he adds. Many avenues are being explored but significant progress is weak. Another track: therapeutic vaccines, a strategy pushed by the laboratory amEricain Moderna.
View comments
1685795820
#immunotherapy #vaccines #raise #hopes
